Post-Approval Patents: The Hidden LOE Risk Map Pharma Teams MissUntil Its Too Late
In pharma, the real fight often doesnt start at approval. It starts after.
Once a drug is approved, the clock doesnt just tick on exclusivityit also ticks on a less visi…
Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…
Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity (and Why It Matters More Than You Think)
Most people hear 20 years and assume the clock is the whole story. Patent terms. Expiration dates. A clean countdown to generic entry.
But in …
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity Read Post »
Pharma mega-deals dont just move moleculesthey move rights.
Behind every headline acquisition, licensing agreement, or strategic partnership sits a quieter question: Which exclusivities actually block competitors, and for how long?
If youre evaluat…
The Four Exclusivities Behind Every Pharma Mega-Deal Read Post »
The Patent Cliff Isnt a CliffIts a Timeline. Heres How to Forecast Drug Price Erosion Before It Hits.
If youve ever watched a blockbusters revenue curve bend downward almost overnight, you already know the punchline: the patent cliff doesnt arrive as a…
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens Read Post »
Post-Approval Isnt AfterIts Where Patent Risk Gets Real
Most pharma teams treat patent strategy like a pre-approval exercise: file early, win early, move on. But the period after approval is where regulatory and IP risk quietly compoundsoften faster th…
Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…
Pharma exclusivity is a chess gameuntil someone files suit.
If youre building a patent strategy, the goal isnt just to have patents. Its to defend exclusivity without triggering the kind of litigation that drains time, cash, and credibility. In today…
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued Read Post »
From Humira to Keytruda: The Blueprint for Surviving the Composition-of-Matter Cliff
The composition-of-matter cliff isnt a metaphorits a calendar. For pharma companies, its the moment when the core patent protection that blocks generic and biosimilar …
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff Read Post »
Pharmas patent cliff isnt just about expiring patents. Its about how those patents are writtenand how quickly the industry can rewrite the story before generic competition arrives.
Thats the hidden lever behind method of use patents: a legal mechanism …
Method-of-Use Patents: The Hidden Lever Rewriting Pharma’s Patent Cliff Math Read Post »
Get new actionable insights and updates from BiotechBlog
